Summary: Asthma and chronic obstructive pulmonary disease (COPD) are the two most common chronic inflammatory lung diseases in Poland. They are the cause of significant medical and social problems, as well as high financial costs. According to the GINA 2022 guidelines, the choice of treatment is determined by the severity of asthma symptoms (degree of asthma control), adherence to medical recommendations by the patient and his personal preferences. The level of treatment intensity should be adjusted to the degree of asthma control. GINA classifies preparations from the group of ICS, LABA and LAMA as drugs controlling the course of the disease and establishes three-drug therapy at the 4th or 5th level of therapy intensity. According to the GOLD 2023 recommendations, the choice of treatment is determined by the risk of exacerbations (small vs. high) and the severity of symptoms (small vs. high based on the results of the CAT or mMRC questionnaires). Triple drug therapy according to the current guidelines found its place in category E of pharmacological treatment of COPD. Several triple therapy drugs are currently available for asthma and COPD. They are discussed in detail in the text. According to the latest global guidelines GINA 2022 and GOLD 2023, triple therapy for asthma and COPD has a well-established scientific and clinical position for the treatment of appropriate groups of patients.